Enterprise Value (EV)
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Vertex Pharmaceuticals Inc., current enterprise value calculation
| Current share price (P) | |
| No. shares of common stock outstanding | |
| US$ in thousands | |
| Common equity (market value)1 | |
| Add: Preferred stock, $0.01 par value; none issued and outstanding (per books) | |
| Total equity | |
| Add: Current finance lease liabilities (per books) | |
| Add: Long-term finance lease liabilities (per books) | |
| Total equity and debt | |
| Less: Cash and cash equivalents | |
| Less: Marketable securities | |
| Enterprise value (EV) | |
Based on: 10-K (reporting date: 2024-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Vertex Pharmaceuticals Inc., EV calculation
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
3 2024 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
- Common equity (market value) and Total equity
- Both common equity (market value) and total equity exhibited a consistent upward trend over the five-year period. Starting at approximately $54.7 billion in 2020, equity rose steadily each year, reaching about $118.8 billion by the end of 2024. This represents more than a doubling of equity within the timeframe, indicating significant growth in the company's market valuation and shareholder equity base.
- Total equity and debt
- Total equity and debt followed a similar increasing pattern as total equity, beginning at roughly $55.3 billion in 2020 and growing to approximately $118.9 billion by 2024. The close alignment between total equity and total equity and debt values suggests that debt levels remained relatively modest compared to equity throughout the period. This stability implies a strong equity-funded capital structure.
- Enterprise value (EV)
- The enterprise value also showed substantial growth, increasing from around $48.6 billion in 2020 to about $112.8 billion in 2024. Although EV grew at a fast pace, the increase was slightly less pronounced than that of total equity and market value, potentially reflecting changes in debt levels or cash balances. Overall, the rising enterprise value mirrors the company’s expanding market capitalization and operational scale.
- Overall financial trends
- The data reflects strong growth over the five-year span in both equity and enterprise value. The consistent increase points to both enhanced investor confidence and effective capital management. The near parallel movement between total equity and total equity plus debt indicates prudent leverage control. This upward trajectory in key valuation metrics suggests favorable performance and growth prospects during the analysed period.